



**Possible modulatory effect of resveratrol on
methotrexate efficacy and pharmacokinetics in a model
of experimentally induced arthritis**

Thesis presented by

Hend Mahmoud Mohamed Rizk

B.Sc, Ain Shams University (2012)

Demonstrator, Department of pharmacology and toxicology, (2013)

Faculty of pharmacy, Ain shams university.

**Submitted to complete the fulfillment of MSc degree in
Pharmaceutical Sciences (Pharmacology and
Toxicology), Faculty of Pharmacy, Ain Shams University.**

Under the supervision of

Prof. Dr. Ebtehal El-Demerdash Zaki

Head of Pharmacology and Toxicology Department

Faculty of pharmacy, Ain shams university

Dr. Reem Nabil Abou El-Naga

**Lecturer of Pharmacology and Toxicology, Faculty of pharmacy, Ain
Shams University**

Faculty of Pharmacy

Ain Shams University

(2017)

Acknowledgements

First and Foremost, I am greatly thankful to Almighty ALLAH for giving me the strength to carry on this work and for blessing me with great people who have been a greatest support along the way. I would like to seize this opportunity to express my sincere gratitude to all those who helped me to complete this work and especially to:

***Prof. Dr. Ebtehal El-Demerdash**, Head of Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, who made this work possible by her great efforts, continuous guidance, support and encouragement throughout the whole stages of this thesis. I am really proud and lucky to have such a passionate supervisor that kept pushing me forward.*

***Dr. Reem Abou El-Naga**, Lecturer at Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, for her endless support, guidance, and help. She was there every step of the way dedicating much of her time to help me with any problems I faced. I am really honored to be a student of such an amazing supervisor.*

Acknowledgements

Dr. Maha Nasr, Associate Professor at Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Ain Shams University, for her great efforts in the preparation of the nano-emulsion formulation.

Dr. Adel Bakeer Kholoussy, Professor of Pathology, Faculty of Veterinary Medicine, Cairo University, for his great effort in accomplishing the part of histopathological technique.

It is my great pleasure to thank all of my friends and colleagues, the members of Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, especially *Eman Mantway, Zeina Hussein, Reham Soliman, Nermine El-Agroudy* and *Sherif Shoeib* who supported me and helped me in my way.

Last but not least, I am forever grateful and thankful to my family, *my parents, my sisters, my brother* and *my great friends* for their continuous support and prayers and for their faith in my abilities to achieve my goals. I would not be where I am today without all of you.

Hend Rizk

List of contents

<i>Subject</i>	<i>Page</i>
<i>List of abbreviations</i>	<i>I</i>
<i>List of Figures</i>	<i>IV</i>
<i>List of Tables</i>	<i>VI</i>
<i>Review of literature</i>	
<i>1. Rheumatoid arthritis</i>	<i>1</i>
<i>2. Animal models of rheumatoid arthritis</i>	<i>27</i>
<i>3. Methotrexate</i>	<i>30</i>
<i>4. Resveratrol</i>	<i>45</i>
<i>Aim of the work</i>	<i>57</i>
<i>Materials and Methods</i>	
<i>A) Design of the work</i>	
<i>Part I- Screening of the optimum dose of resveratrol for modulation of anti-arthritis effects of methotrexate</i>	<i>58</i>
<i>Part II- Studying the underlying mechanisms of the modulatory effect of resveratrol on the anti-arthritis effects of methotrexate</i>	<i>60</i>
<i>B) Materials</i>	<i>64</i>
<i>C) Methods</i>	<i>68</i>
<i>Results</i>	<i>101</i>
<i>Discussion</i>	<i>158</i>
<i>Summary and Conclusion</i>	<i>171</i>
<i>References</i>	<i>178</i>
<i>Arabic Summary</i>	

List of Abbreviations

ACR	<i>The American College of Rheumatology</i>
AIA	<i>Adjuvant induced arthritis</i>
AICAR	<i>5-aminoimidazole-4-carboxamide ribonucleotide</i>
ANOVA	<i>Analysis of variance</i>
CFA	<i>Complete Freund's adjuvant</i>
CIA	<i>Collagen induced arthritis</i>
COX-2	<i>Cyclooxygenase 2</i>
CVDs	<i>Cardiovascular diseases</i>
DHFR	<i>Dihydro-folate reductase</i>
DMARDs	<i>Disease modifying anti-rheumatic drugs</i>
DMSO	<i>Dimethyl sulfoxide</i>
ELISA	<i>Enzyme-linked immunosorbent assay</i>
FLS	<i>Fibroblast like synoviocytes</i>
GM-CSF	<i>Granulocyte-macrophage colony-stimulating factor</i>
H&E	<i>Hematoxylin and Eosin</i>
HLA-DR	<i>Human Leukocyte Antigen - antigen D Related</i>
IFN- γ	<i>Interferon gamma</i>
Ig	<i>Immunoglobulins</i>

List of abbreviations

<i>IL</i>	<i>Interleukin</i>
<i>i.p</i>	<i>Intraperitoneal</i>
<i>MMPs</i>	<i>Matrix metalloproteinases</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>MTX</i>	<i>Methotrexate</i>
<i>NaOH</i>	<i>Sodium hydroxide</i>
<i>NF-κB</i>	<i>Nuclear factor kappa-light-chain-enhancer of activated B cells</i>
<i>NK</i>	<i>Natural killer</i>
<i>NSAIDs</i>	<i>Non-Steroidal anti-inflammatory drugs</i>
<i>OPG</i>	<i>Osteoprotegerin</i>
<i>PG</i>	<i>Prostaglandins</i>
<i>RA</i>	<i>Rheumatoid arthritis</i>
<i>RANKL</i>	<i>Receptor activator of NF-KB ligand</i>
<i>RF</i>	<i>Rheumatoid factor</i>
<i>RFC₁</i>	<i>Reduced folate carrier 1</i>
<i>RSV</i>	<i>Resveratrol</i>
<i>s.c</i>	<i>Subcutaneous</i>
<i>SD</i>	<i>Standard deviation</i>
<i>TGF-β</i>	<i>Transforming growth factor beta</i>
<i>Th17</i>	<i>T-helper 17 cells</i>

List of abbreviations

<i>THF</i>	<i>Tetrahydro-folate</i>
<i>TNF-α</i>	<i>Tumor necrosis factor-alpha</i>
<i>TRAF</i>	<i>TNF receptor-associated factor</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>

List of Tables

No.	Title	Page
A	Arthritic scoring system	69
B	Gait scoring system	70
1	Effect of methotrexate and resveratrol on arthritic index score in adjuvant arthritic rats	102
2	Effect of methotrexate and resveratrol on gait score in adjuvant arthritic rats	105
3	Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats	109
4	Effect of methotrexate and resveratrol on hind paw volume in adjuvant arthritic rats	113
5	Histopathological grading	118
6	Effect of methotrexate and resveratrol on arthritic index score in adjuvant arthritic rats	120
7	Effect of methotrexate and resveratrol on gait score in adjuvant arthritic rats	123
8	Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats	127
9	Effect of methotrexate and resveratrol on hind paw volume in adjuvant arthritic rats	132
10	Effect of methotrexate and resveratrol on paw tissue TNF- α level in adjuvant arthritic rats	136
11	Effect of methotrexate and resveratrol on paw tissue IL-17 level in adjuvant arthritic rats	141
12	Effect of methotrexate and resveratrol on paw tissue RANKL level in adjuvant arthritic rats	146
13	Effect of methotrexate and resveratrol on paw tissue Caspase 3 activity in adjuvant arthritic rats	151
14	Histopathological grading	157

List of Figures

No.	Title	Page
A	<i>Schematic view of the synovial membrane (or synovium) and its cell types</i>	6
B	<i>Pathways leading to activation of synovial T cells in RA and their key effector pathways</i>	9
C	<i>Pathogenesis of RA: synovial and systemic inflammation</i>	15
D	<i>Positive regulators of osteoclastogenesis and bone resorption in RA</i>	16
E	<i>Some folate-dependent enzymes inhibited by MTX and MTX polyglutamates</i>	34
F	<i>Structure similarity between dihydrofolate and methotrexate</i>	36
G	<i>Chemical structures of resveratrol isomers</i>	52
H	<i>Standard curve of TNF-α</i>	78
I	<i>Standard curve of IL-17</i>	85
J	<i>Standard curve of sRANKL</i>	90
K	<i>Standard curve of Caspase 3</i>	96
1	<i>Effect of methotrexate and resveratrol on arthritic index score in adjuvant arthritic rats on day 21</i>	103
2	<i>Effect of methotrexate and resveratrol on gait score in adjuvant arthritic rats on day 21</i>	106
3a	<i>Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats</i>	110
3b	<i>Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats on day 21</i>	111
4a	<i>Effect of methotrexate and resveratrol on hind paw volume in adjuvant arthritic rats</i>	114
4b	<i>Effect of methotrexate and resveratrol on hind paw volume in adjuvant arthritic rats on day 21</i>	115
5	<i>Representative photomicrographs of hind paw sections stained by H&E</i>	117

6	<i>Effect of methotrexate and resveratrol on arthritic index score in adjuvant arthritic rats on day 21</i>	121
7	<i>Effect of methotrexate and resveratrol on the gait score in adjuvant arthritic rats on day 21</i>	124
8a	<i>Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats</i>	128
8b	<i>Effect of methotrexate and resveratrol on ankle diameter in adjuvant arthritic rats on day 21</i>	129
9a	<i>Effect of methotrexate and resveratrol on hind paw volume in adjuvant arthritic rats</i>	133
9b	<i>Effect of methotrexate and resveratrol on hind paw volumes in adjuvant arthritic rats on day 21</i>	134
10	<i>Effect of methotrexate and resveratrol on paw tissue TNF-α level in adjuvant arthritic rats</i>	137
11	<i>Expression of NF-κB in hind paw sections by immunohistochemical staining</i>	139
12	<i>Effect of methotrexate and resveratrol on paw tissue IL-17 level in adjuvant arthritic rats</i>	142
13	<i>Expression of COX-2 in hind paw sections by immunohistochemical staining</i>	144
14	<i>Effect of methotrexate and resveratrol on paw tissue RANKL level in adjuvant arthritic rats</i>	147
15	<i>Expression of MMP-9 in hind paw sections by immunohistochemical staining</i>	149
16	<i>Effect of methotrexate and resveratrol on paw tissue Caspase 3 activity in adjuvant arthritic rats</i>	152
17	<i>Expression of cyt c in hind paw sections by immunohistochemical staining</i>	154
18	<i>Representative photomicrographs of hind paw sections stained by H&E</i>	156

Abstract

Background: Low dose methotrexate is the cornerstone of rheumatoid arthritis treatment. However, it is seldom used alone and almost usually combined with other anti-rheumatic agents which increases the risk of toxicity. **Objective:** The present study aimed to investigate the modulatory effect of resveratrol on the efficacy of methotrexate, in addition to elucidating the possible mechanisms for this modulatory effect, and also testing the effect of nano-encapsulation of resveratrol on improving this modulatory effect. **Methods:** Complete Freund's adjuvant was used to induce arthritis. Arthritic rats were treated with methotrexate and resveratrol (solution)/resveratrol nano-emulsion. Arthritic score, gait score, ankle diameter, paw volume and histopathology were determined to assess the anti-arthritic effects. Tissue TNF- α , IL-17 levels, and COX-2 activity were evaluated to study the anti-inflammatory effect. While tissue RANKL, and MMP-9 levels were measured to study the effect on bone and cartilage erosion. Finally, tissue caspase-3 activity and cytochrome c level were evaluated to study the effect on apoptosis. **Results:** Combination therapy of resveratrol (50 mg/kg) with methotrexate significantly improved arthritic parameters as compared to methotrexate alone. It also alleviated adjuvant induced inflammation, bone/ cartilage erosion, synovial proliferation, and pannus formation. Moreover, using resveratrol in nano-emulsion form gave the same modulatory effect when given at half the dose administered of the conventional formula. **Conclusion:** resveratrol potentiates the anti-arthritic effects of methotrexate, possibly by acting as anti-inflammatory, and pro-apoptotic. Furthermore, resveratrol nano-encapsulation further improves the modulatory effect of resveratrol on methotrexate efficacy.

Keywords: *Resveratrol - Methotrexate - Adjuvant arthritis – nano-emulsion.*

*Review of
Literature*

1. Rheumatoid Arthritis

1.1. Background:

Rheumatoid arthritis (RA), is a chronic autoimmune inflammatory disorder which affects the joints and is associated with swelling, stiffness, and pain (**Fishman and Bar-Yehuda, 2010**). It is usually also accompanied by variable extra-articular manifestations (**Grasasi et al., 1998**).

There are skeletal remains from North America indicating that the disease existed at least 3000 years ago, and it was given its name by Alfred Baring Garrod in 1859 (**Parish, 1963**). As the causes of RA are still unknown, cures have not been discovered yet as well. All treatments and therapies which are applied so far are intended largely to reduce symptoms and delay the progress of the disease (**Newman, 1996**).

Rheumatoid arthritis has been regarded by many as an autoimmune disease whereby the body's immune system attacks its own tissues, based upon the findings of auto-reactivity to collagen type II (**Tarkowski et al., 1989**), and to non-cartilaginous proteins, for example filaggrin or citrullinated peptides (**Schellekens et al., 1998a**). A further support for the role of autoimmunity in RA is the presence of rheumatoid factors, commonly regarded as autoantibodies against the Fc region of human IgG. They are present in about 80% of RA patients,

although they are not specific for RA, but occur in many inflammatory disorders, and in symptomless arthritic patients as well (**Ingegnoli et al., 2013**). The clinical appearance of RA differs so much between individual patients, that one sometimes is tempted to believe that the patients do not have the same disease. (**Arvidson, 2003**).

1.2. Prevalence:

The prevalence of RA is estimated to be about 1% in most European populations, with a lower prevalence reported for people of Asian and African origin. (**Mody and Cardiel, 2008**). Prevalence data for RA are now becoming available for many of the developing countries around the world, reporting a prevalence in urban settings that ranges from 0.1% in Algeria (**Slimani and Ladjouze-Rezig, 2014**), 0.6% in the DRC (**Malemba et al., 2012**), to an overall prevalence of 2.5% in South Africa (**Solomon et al., 1975**), and in rural settings that ranges from an overall prevalence of 0.07% in South Africa (**Beighton et al., 1975**), 0.3% in Egypt (**Usenbo et al., 2015**), to 0.4% in Lesotho (**Moolenburgh et al., 1986**).

Females are found to be three times more affected than males (**Anderson et al., 2004**). Clinically, RA is more prevalent in women before age 50 but is more severe in women after 50 (**Straub, 2007**). However some small studies from Nigeria, Liberia, and South Africa showed a high male to female ratio that was inconsistent with global findings (**Usenbo et al., 2015**).